Should I buy or sell Castle Biosciences stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Castle Biosciences in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CSTL shares. View CSTL analyst ratings or view top-rated stocks .

What is Castle Biosciences' stock price target for 2024?

3 brokers have issued 1-year target prices for Castle Biosciences' shares. Their CSTL share price targets range from $25.00 to $37.00. On average, they expect the company's share price to reach $31.00 in the next year. This suggests a possible upside of 61.0% from the stock's current price. View analysts price targets for CSTL or view top-rated stocks among Wall Street analysts .

How have CSTL shares performed in 2024?

Castle Biosciences' stock was trading at $21.58 at the beginning of 2024. Since then, CSTL stock has decreased by 10.8% and is now trading at $19.25. View the best growth stocks for 2024 here .

When is Castle Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our CSTL earnings forecast .

How can I listen to Castle Biosciences' earnings call?

Castle Biosciences will be holding an earnings conference call on Thursday, May 2nd at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link .

How were Castle Biosciences' earnings last quarter?

Castle Biosciences, Inc. (NASDAQ:CSTL) posted its quarterly earnings results on Wednesday, February, 28th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.84) by $0.74. The company had revenue of $66.12 million for the quarter, compared to analyst estimates of $51.32 million. Castle Biosciences had a negative trailing twelve-month return on equity of 14.92% and a negative net margin of 26.15%.

What ETF holds Castle Biosciences' stock?

First Trust Nasdaq Lux Digital Health Solutions ETF holds 98 shares of CSTL stock, representing 0.21% of its portfolio.

What guidance has Castle Biosciences issued on next quarter's earnings?

Castle Biosciences issued an update on its FY 2024 earnings guidance on Wednesday, February, 28th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $235.0 million-$240.0 million, compared to the consensus revenue estimate of $214.7 million.

What other stocks do shareholders of Castle Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Castle Biosciences investors own include AbbVie (ABBV) , Advanced Micro Devices (AMD) , NVIDIA (NVDA) , Block (SQ) , DexCom (DXCM) , QUALCOMM (QCOM) , Teladoc Health (TDOC) , Applied Materials (AMAT) , Incyte (INCY) and Intel (INTC) .

When did Castle Biosciences IPO?

Castle Biosciences (CSTL) raised $50 million in an initial public offering (IPO) on Thursday, July 25th 2019. The company issued 3,300,000 shares at a price of $14.00-$16.00 per share. SVB Leerink and Baird acted as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers.

How do I buy shares of Castle Biosciences?

Shares of CSTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:CSTL

Castle Biosciences (CSTL) Stock Price, News & Analysis

→ Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (From Priority Gold) (Ad)

Free CSTL Stock Alerts

$19.20

+0.36 (+1.91%)

(As of 03:33 PM ET)

Compare

Today's Range: $18.50
▼
$19.38
50-Day Range: $18.06
▼
$25.30
52-Week Range: $9.26
▼
$26.70

Volume: 80,662 shs
Average Volume: 236,184 shs
Market Capitalization: $527.04 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $31.00

Get Castle Biosciences alerts:

Castle Biosciences MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 61.0% Upside
$31.00 Price Target
Short Interest: Bearish
5.21% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.59
Based on 5 Articles This Week
Insider Trading: Selling Shares
$1.05 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($2.41) to ($2.28) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.89 out of 5 stars

Medical Sector

649th out of 914 stocks

Medical Laboratories Industry

16th out of 20 stocks

3.5

Analyst's Opinion

Consensus Rating
Castle Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Castle Biosciences has only been the subject of 2 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
5.21% of the outstanding shares of Castle Biosciences have been sold short.
Short Interest Ratio / Days to Cover
Castle Biosciences has a short interest ratio ("days to cover") of 5.7.
Change versus previous month
Short interest in Castle Biosciences has recently increased by 0.70%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Castle Biosciences does not currently pay a dividend.
Dividend Growth
Castle Biosciences does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CSTL.

2.6

News and Social Media Coverage

News Sentiment
Castle Biosciences has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for Castle Biosciences this week, compared to 4 articles on an average week.
Search Interest
Only 3 people have searched for CSTL on MarketBeat in the last 30 days. This is a decrease of -70% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Castle Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,051,065.00 in company stock.
Percentage Held by Insiders
Only 7.70% of the stock of Castle Biosciences is held by insiders.
Percentage Held by Institutions
92.60% of the stock of Castle Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Castle Biosciences are expected to grow in the coming year, from ($2.41) to ($2.28) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Castle Biosciences is -8.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Castle Biosciences is -8.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Castle Biosciences has a P/B Ratio of 1.32. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Priority Gold

Biden to Launch “FedNOW” [Move Your Money Now]

Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentially cancel your money. You see Biden and the Fed have teamed up to create a controllable, traceable, programmable digital currency to replace the dollar...

Get your free information kit NOW, before it's too late.

About Castle Biosciences Stock (NASDAQ:CSTL)

Castle Biosciences, Inc., a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus. In addition, the company provides DecisionDx-UM test, a proprietary risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide drug treatment for major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. It offers its products to skin cancer, gastroenterology, and mental health markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.

CSTL Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CSTL Stock News Headlines

April 18, 2024 | insidertrades.com

Insider Selling: Castle Biosciences, Inc. (NASDAQ:CSTL) Insider Sells 1,947 Shares of Stock

April 11, 2024 | insidertrades.com

Castle Biosciences, Inc. (NASDAQ:CSTL) Director Daniel Bradbury Sells 2,400 Shares

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 9, 2024 | insidertrades.com

Castle Biosciences, Inc. (NASDAQ:CSTL) Director Daniel Bradbury Sells 9,152 Shares

April 6, 2024 | insidertrades.com

Insider Selling: Castle Biosciences, Inc. (NASDAQ:CSTL) Insider Sells 2,368 Shares of Stock

March 24, 2024 | insidertrades.com

Derek J. Maetzold Sells 2,295 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) Stock

April 18, 2024 | investing.com

Castle Biosciences CEO sells over $100k in company stock

April 17, 2024 | finance.yahoo.com

We're Not Worried About Castle Biosciences' (NASDAQ:CSTL) Cash Burn

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 12, 2024 | americanbankingnews.com

Daniel Bradbury Sells 2,400 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) Stock

April 11, 2024 | businesswire.com

Castle Biosciences to Release First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 2, 2024

April 10, 2024 | finance.yahoo.com

Castle Biosciences Celebrates Esophageal Cancer Awareness Month through Advocacy and Educational Collaborations

April 10, 2024 | businesswire.com

Castle Biosciences Celebrates Esophageal Cancer Awareness Month through Advocacy and Educational Collaborations

April 10, 2024 | finance.yahoo.com

Castle Biosciences’ Chief Financial Officer Frank Stokes Recognized as a Top CFO of Houston for Second Consecutive Year

April 10, 2024 | businesswire.com

Castle Biosciences' Chief Financial Officer Frank Stokes Recognized as a Top CFO of Houston for Second Consecutive Year

April 10, 2024 | investing.com

Castle Biosciences director sells over $440k in company stock

April 5, 2024 | finance.yahoo.com

What Makes Castle Bioscience (CSTL) a Prospective Investment?

April 4, 2024 | finance.yahoo.com

Presentations at EADO Highlight Potential Impact of Castle Biosciences’ DecisionDx®-Melanoma and DecisionDx®-SCC Tests on the Management of Patients with Skin Cancer

April 4, 2024 | businesswire.com

Presentations at EADO Highlight Potential Impact of Castle Biosciences' DecisionDx®-Melanoma and DecisionDx®-SCC Tests on the Management of Patients with Skin Cancer

March 27, 2024 | businesswire.com

Castle Biosciences Announces Updates to its Board of Directors

March 25, 2024 | finance.yahoo.com

Castle Biosciences Earns a Top Workplaces USA Award for the Third Consecutive Year

March 22, 2024 | businesswire.com

Long-term Outcomes Data Shared at SSO 2024 Show That Patients with a Low-Risk DecisionDx®-Melanoma Test Result Were Recurrence Free at Three Years, Including Those Who Utilized the Test to Help Guide the Decision to Avoid an SLNB

March 20, 2024 | finance.yahoo.com

Does Castle Bioscience (CSTL) Have Robust Growth Prospects?

March 19, 2024 | businesswire.com

Leading Squamous Cell Carcinoma Practitioners Publish Consensus Guidelines Integrating DecisionDx®-SCC into a Clinical Workflow to Improve Decision-Making Regarding the Use of Adjuvant Radiation Therapy

March 16, 2024 | finance.yahoo.com

CSTL Apr 2024 17.500 call

March 15, 2024 | finance.yahoo.com

New Study Shows that the Drug-Drug Interactions and Lifestyle Factors Provided by Castle Biosciences’ IDgenetix® Test Significantly Improve Medication Recommendations Over Drug-Gene Interactions Alone for Patients 65 and Older

March 15, 2024 | businesswire.com

New Study Shows that the Drug-Drug Interactions and Lifestyle Factors Provided by Castle Biosciences' IDgenetix® Test Significantly Improve Medication Recommendations Over Drug-Gene Interactions Alone for Patients 65 and Older

See More Headlines

Receive CSTL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Castle Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/28/2024
Today: 4/18/2024
Next Earnings (Confirmed): 5/02/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Medical laboratories
Sub-Industry: N/A
Current Symbol: NASDAQ:CSTL
CUSIP: N/A
CIK: 1447362
Web: castlebiosciences.com
Phone: (866) 788-9007
Fax: N/A
Employees: 610
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $31.00
High Stock Price Target: $37.00
Low Stock Price Target: $25.00
Potential Upside/Downside: +61.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.16)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-57,470,000.00
Net Margins: -26.15%
Pretax Margin: -26.10%
Return on Equity: -14.92%
Return on Assets: -13.20%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.20
Quick Ratio: 6.04

Sales & Book Value

Annual Sales: $219.79 million
Price / Sales: 2.41
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $14.54 per share
Price / Book: 1.32

Miscellaneous

Outstanding Shares: 27,450,000
Free Float: 25,336,000
Market Cap: $528.69 million
Optionable: Optionable
Beta: 0.93

These 7 Stocks Will Be Magnificent in 2024

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

Mr. Derek J. Maetzold (Age 62)
Founder, CEO, President & Director
Comp: $1.45M
Mr. Frank Stokes (Age 53)
CFO & Treasurer
Comp: $849.36k
Ms. Kristen M. Oelschlager R.N. (Age 56)
Chief Operating Officer
Comp: $782.7k
Mr. Tobin W. Juvenal (Age 64)
Chief Commercial Officer
Comp: $782.7k
Camilla Zuckero
Vice President of Investor Relations & Corporate Affairs
Ms. Alice Bahner Izzo
Senior Vice President of Marketing
Mr. Kevin Doman
Vice President of Sales
Ms. Keli Greenberg
VP of Human Resources & Executive Director of Human Resources
Dr. Robert W. Cook Ph.D. (Age 52)
Senior Vice President of Research & Development
Dr. Matthew Goldberg M.D.
Senior Vice President of Medical

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CSTL Stock Analysis - Frequently Asked Questions

Should I buy or sell Castle Biosciences stock right now?: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Castle Biosciences in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CSTL shares.
View CSTL analyst ratings or view top-rated stocks.
What is Castle Biosciences' stock price target for 2024?: 3 brokers have issued 1-year target prices for Castle Biosciences' shares. Their CSTL share price targets range from $25.00 to $37.00. On average, they expect the company's share price to reach $31.00 in the next year. This suggests a possible upside of 61.0% from the stock's current price.
View analysts price targets for CSTL or view top-rated stocks among Wall Street analysts.
How have CSTL shares performed in 2024?: Castle Biosciences' stock was trading at $21.58 at the beginning of 2024. Since then, CSTL stock has decreased by 10.8% and is now trading at $19.25.
View the best growth stocks for 2024 here.
When is Castle Biosciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our CSTL earnings forecast.
How can I listen to Castle Biosciences' earnings call?: Castle Biosciences will be holding an earnings conference call on Thursday, May 2nd at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.
How were Castle Biosciences' earnings last quarter?: Castle Biosciences, Inc. (NASDAQ:CSTL) posted its quarterly earnings results on Wednesday, February, 28th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.84) by $0.74. The company had revenue of $66.12 million for the quarter, compared to analyst estimates of $51.32 million. Castle Biosciences had a negative trailing twelve-month return on equity of 14.92% and a negative net margin of 26.15%.

What ETF holds Castle Biosciences' stock?: First Trust Nasdaq Lux Digital Health Solutions ETF holds 98 shares of CSTL stock, representing 0.21% of its portfolio.
What guidance has Castle Biosciences issued on next quarter's earnings?: Castle Biosciences issued an update on its FY 2024 earnings guidance on Wednesday, February, 28th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $235.0 million-$240.0 million, compared to the consensus revenue estimate of $214.7 million.
What other stocks do shareholders of Castle Biosciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Castle Biosciences investors own include AbbVie (ABBV), Advanced Micro Devices (AMD), NVIDIA (NVDA), Block (SQ), DexCom (DXCM), QUALCOMM (QCOM), Teladoc Health (TDOC), Applied Materials (AMAT), Incyte (INCY) and Intel (INTC).
When did Castle Biosciences IPO?: Castle Biosciences (CSTL) raised $50 million in an initial public offering (IPO) on Thursday, July 25th 2019. The company issued 3,300,000 shares at a price of $14.00-$16.00 per share. SVB Leerink and Baird acted as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers.
How do I buy shares of Castle Biosciences?: Shares of CSTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CSTL) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial